Abstract
• Introduction • Dynamics between endothelial injury and repair:
the response to injury theory 'revisited' • Emerging biomarkers reflecting the dynamics between endothelial injury and repair: from pathophysiology to clinical testing.
-Circulating endothelial cells -Endothelial microparticles -Endothelial progenitor cells • Endothelial lesion versus regeneration: towards the definition of 'vascular competence' • Conclusion

Introduction
Strategically located between blood and tissues, the endothelium is exposed to blood-borne mediators, biomechanical stimuli and cells from circulating blood and neighbouring tissues, which determines a switch from a quiescent to an activated phenotype. Such activated phenotype, resulting from the physiological adaptation of a given region, can also occur pathophysiologically.
It is now well recognized that disruption of endothelial integrity and physiological functions represent a pivotal mechanism in the initiation and development of cardiovascular disorders (CVD) [1] .
Consequently, exploration of endothelium has raised growing interest and has led to the development of a range of methods that can be divided into functional testing and surrogate biomarkers.
The former includes endothelium-dependent vasorelaxation, arterial stiffness and pulse wave propagation, and has recently been reviewed [2] 
(CEC) and endothelial-derived microparticles (EMP) released from the injured vessels and progenitors endothelial cells (EPC) involved in vascular regeneration.
Since CEC, EMP and EPC have been individually reviewed [3] [4] [5] [6] [7] [8] , the present review aims to summarize the novel insight provided by these emerging cellular biomarkers (i) 
in the current understanding of the endothelial dynamics between injury and repair, (ii) in the evaluation of vascular integrity in a specific and non-invasive way and (ii) in the assessment of vascular risk. This review will also discuss the promises of multimarker strategies combining CEC, and EMP and EPC as integrative markers of vascular competence, an emerging concept for vascular risk stratification and therapeutic options.
Dynamics between endothelial injury and repair: the response to injury theory 'revisited'
Initially viewed as a single-cell lining of the vascular system, the endothelium has emerged as a dynamically mutable interface locally responsive to environmental stimuli. As a consequence, reprogramming of the endothelium generates an impressive repertoire of biological responses playing a key role in the control of vascular homeostasis such as vasomotion, permeability, haemostasis, inflammation or angiogenesis [9] . According to the response to injury theory [10] , mechanical damage or chronic exposure to cardiovascular risk factors (CRF) alters the regulatory functions of the endothelium, which progress towards pro-inflammatory activation, senescence and apoptosis (Fig. 1) . As a consequence, the endothelium not only displays altered functions, but also loses its integrity. Microparticles released from activated or apoptotic endothelial cells [11] and endothelial cells detached from injured vessels [12] [12] .
IMS assay has become the consensus protocol for CEC enumeration [17] . This method combines a first step of enrichment using CD146 coated magnetic microbeads and a second step of 
Ulex Europaeus lectin 
Endothelial microparticles
The first description of endothelial microparticles (EMP) was done in patients with lupus anticoagulant presenting thrombotic complications [11] [53] . The presence of pro-coagulant EMP has also been found in atherosclerotic plaques [54] and in the circulation of patients with ACS [55] . However, MP generated from cultured endothelial cells stimulated with activated protein C harbour functional endothelial protein C receptor, protected from metalloproteinase cleavage, and display anticoagulant ability towards factor Va inactivation [56] . Although this mechanism is [60] .
A survey of the literature, summarized in Table 3 , indicated that elevated EMP levels have been reported in CVD and other vascular settings associated with a thrombotic propensity [6, 74] . Elevated EMP levels are also associated with most of the CRF such as obesity [75] , hypertension [63] , diabetes [65, 66] [78] and thrombus formation in vivo [54, 79] . In addition, EMP amplify endothelial dysfunction by impairing nitric oxide pathways, as shown by alteration to acetyl choline-induced relaxation using the rat aortic ring model [80] .
Besides their role as pro-coagulant effectors, recent findings support the concept that MP also behave as vectors of plasminogenolytic activity due to the expression of the uPA/uPAR system, a mechanism that modulates the angiogenic response of endothelial progenitors in vitro [81] . MP exposes other proteases such as metalloproteinase 2 and 9 that affect vascular remodelling and angiogenesis [82] . Such data have led to the concept that EMP are key factors at the crossroads between inflammation, coagulation, proteolysis and vascular repair.
Endothelial progenitor cells
Since the pioneer's work of Asahara [83] [115] . By contrast, classical CRF such as diabetes, age or uraemia negatively affect EPC. [116] .
The impact of CRF in the reduction of EPC availability is still poorly defined. However, several mechanisms have been put forward such as (i) exhaustion of the pool of stem/progenitor cells in the bone marrow, (ii) defective mobilization due to altered stem cell niche involving reduced nitric oxide bioavailabilty, (iii) impaired homing caused by reduction of chemoattractive factor synthesis or disturbance of their receptor-mediated signalling pathways and (iv) increased apoptosis and/or deregulated differentiation. This latter effect may involve intrinsic EPC defect or change in the local environment that determines cell fate either towards endothelial lineage or towards inflammatory cells or smooth muscle cells promoting atherosclerosis
Early clinical studies, summarized in Table 4 [147, 148] . EPC defects have also been linked to situations that strengthen cardiovascular risk [149] , such as diabetes mellitus [131, 132] , hypertension [150] , chronic renal failure [139] , aging [151] or smoking [143] . The relationship between EPC reduction and CRF has been convincingly established in patients at various stages of atherosclerosis [152] [153] [154] . Decreased EPC levels and migratory activity were observed in CAD patients compared to controls and were found to inversely correlate with the number of CRF [117] (Fig. 2) [114] Continued... [122] Heart failure CD34 ϩ EPC inversely correlate with disease severity [123] 
Endothelial lesion versus regeneration: towards the definition of 'vascular competence'
Current evidence suggests that regenerative versus degenerative endothelial responses can be integrated in a clinical endothelial phenotype, reflecting the net result between damage from risk factors and endogenous repair capacity. This endothelial phenotype characterizes a vascular status that could define the 'vascular competence' of each individual. Because CEC, EMP and EPC are key players of the endothelial homeostatic balance, their combined measurement offers a non-invasive and original way to estimate vascular competence at the individual level
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